Physician profile
Bashar Sileewa
NPI 1174087829
$1,859.28
in general payments reported to CMS, 2019-2025
13 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2022: $179 · 2023: $292 · 2024: $807 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $500.15 | 2023-2025 | Xifaxan, Plenvu |
| Abbvie INC. | $420.80 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $158.62 | 2024-2025 | Tremfya, Stelara |
| Redhill Biopharma INC. | $141.93 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $130.55 | 2022 | |
| Janssen Biotech, INC. | $121.86 | 2024 | Stelara, Tremfya |
| Gilead Sciences, INC. | $107.10 | 2023 | Vemlidy |
| Pfizer INC. | $104.60 | 2024 | |
| Intercept Pharmaceuticals, INC. | $98.05 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $28.80 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.15 | 2023 | Entyvio |
| Qol Medical, LLC | $15.47 | 2023 | Sucraid |
| Braintree Laboratories, INC. | $15.20 | 2023 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Sileewa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.